Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303

L. Bartlett, Nancy; H. Wilson, Wyndham; Jung, Sin‐Ho; D. Hsi, Eric; J. Maurer, Matthew; Pederson, Levi; C. Polley, Mei‐Yin; N. Pitcher, Brandelyn; D. Cheson, Bruce; S. Kahl, Brad; W. Friedberg, Jonathan; M. Staudt, Louis; D. Wagner‐Johnston, Nina; A. Blum, Kristie; S. Abramson, Jeremy; Reddy, Nishitha; N. Winter, Jane; Chang, Julie; K. Gopal, Ajay; Chadburn, Amy; Mathew, Susan; I. Fisher, Richard; L. Richards, Kristy; Schöder, Heiko; D. Zelenetz, Andrew; P. Leonard, John

doi:10.1200/jco.18.01994

Public

Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303

Published in Journal of Clinical Oncology • Apr 2, 2019

Authors:

Nancy L. Bartlett

Wyndham H. Wilson

Sin‐Ho Jung

Abstract

PURPOSE Alliance/CALGB 50303 (NCT00118209), an intergroup, phase III study, compared dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R) with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) as frontline t...

Subject

Medicine

Internal medicine

Vincristine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!